People in the daratumumab group who stayed MRD negative for at least a year were able to stop taking daratumumab as maintenance therapy and remained cancer free. That’s important, Dr. Sonneveld said, because taking fewer drugs long-term for maintenance therapy often translates to a better well-being and quality of life.
Adding daratumumab to the standard treatment resulted in a nearly 60% drop in the risk of cancer progression or death (hazard ratio of 0.42), the researchers determined.
The magnitude of that change is “unprecedented in these kinds of phase 3 trials [for] multiple myeloma,” Dr. Sonneveld said.
Leave a reply